Efficiently Creating Value with Innovative Science


NASDAQ: OXGN

$ 2.15 0.18 (9.14%)
Day High: 2.23
Day Low:  2.01
Volume:    1,585,500
4:00 PM ET
Oct 24, 2014

Delayed ~20 min., by eSignal.

Press Releases

 
Press Releases
Date Title and Summary View
Oct 22, 2014 SOUTH SAN FRANCISCO, Calif., Oct. 22, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will hold a conference call and webcast on Wednesday, November 12, 2014 at 4:30 p.m. ET (1:30 p.m. PT). During the call, members of the OXiGENE management team will pro...
Oct 7, 2014 SOUTH SAN FRANCISCO, Calif., Oct. 7, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the first patient has been enrolled in a Phase 1b/2 clinical study that will evaluate fosbretabulin in combination with Votrient™ (pazopanib) in patients with recurre...
Oct 6, 2014 South San Francisco, Calif., October 6, 2014 - OXiGENE, Inc. (NASDAQ:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the data from the Phase 2 GOG186I study of fosbretabulin in combination with bevacizumab will be presented on Sunday, November 9 at the 15th Biennial Meeting of the Internationa...
Sep 17, 2014 SOUTH SAN FRANCISCO, Calif., Sept. 17, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that the first patient has been enrolled in a Phase 2 study to evaluate the safety and activity of fosbretabulin monotherapy in patients with locally advanced, recurrent or me...
Aug 26, 2014 SOUTH SAN FRANCISCO, Calif., Aug. 26, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that David Chaplin, Ph.D., CEO, will present a corporate overview at the Rodman and Renshaw Annual Global Investment conference on Tuesday, September 9, 2014 ...
Aug 5, 2014 - Phase 2 Trial of Fosbretabulin in Gastrointestinal Neuroendocrine Tumors Planned - - Further Data from Gynecologic Oncology Group (GOG) Phase 2 Ovarian Cancer Trial to be Presented in November - - Cash Balance Increased to $36.3 Million - SOUTH SAN FRANCISCO, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:O...
Jul 23, 2014 SOUTH SAN FRANCISCO, Calif., July 23, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report second quarter 2014 results on Tuesday, August 5, 2014. A conference call and webcast hosted by OXiGENE management will begin at 4:30 p.m. ET (1:30 p.m. PT)...
May 23, 2014 SOUTH SAN FRANCISCO, Calif., May 23, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced that it has entered into definitive agreements with institutional investors to purchase an aggregate of $16 million of registered shares of OXiGENE common stock in an at-the-mar...
May 16, 2014 SOUTH SAN FRANCISCO, Calif., May 16, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that David (Dai) Chaplin, Ph.D., has been appointed to the position of President and Chief Executive Officer, replacing Peter Langecker, M.D., Ph.D. Dr...
May 6, 2014 Company Strengthens Cash Position by $20 Million Announced Positive Phase 2 Data in Recurrent Ovarian Cancer for ZYBRESTAT® in Combination With Avastin® SOUTH SAN FRANCISCO, Calif., May 6, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to trea...
Page:
1
... NextLast
= add release to Briefcase